Brief: US Patent board rules for Biogen in Forward patent case
31/03/2017 17:15
March 31 (Reuters) - Forward Pharma A/S FWP.O
* US Patent Trial and Appeal Board ruling is about
"interference" and follows earlier ruling for biogen on ipr
Further company coverage: FWP.O BIIB.O
(Reporting By Caroline Humer)
((caroline.humer@thomsonreuters.com;))
Recent news on Forward Pharma A/S
See all newsBrief: Forward Pharma- Announces Termination Of Its American Depositary Receipts Facility
U.S. STOCKS ON THE MOVE-Madrigal, Disney, Forward Pharma
Forward Pharma slides to record low on delisting notice from Nasdaq
Brief: Forward Pharma Announces Delisting Its American Depositary Shares From Nasdaq Capital Market
Brief: Forward Pharma A/S Submitted A Request For A Written Decision Regarding Petition For Review Regarding EP2801355 To The EBA